Azilsartan Impurity 19(CAS: 1403474-70-3)

Azilsartan Impurity 19 (CAS: 1403474-70-3) should comply with the REACH regulations in the European Union, which require manufacturers and importers to register substances and evaluate their safety. In the United States, it must also adhere to FDA guidelines for the import and sale of chemical substances, as well as EPA regulations for handling and disposal. Additionally, it should follow GHS classification for hazardous substances and ensure proper labeling and safety data sheets are provided.

In the synthesis of azilsartan, alternative reagents such as 1H-indazole or 2-amino-4-(1H-indazol-5-yl)benzene can be used as precursors. Isomers and analogs of Azilsartan Impurity 19 may also serve as viable alternatives, but thorough testing is necessary to ensure they meet the required specifications and do not introduce unwanted impurities.

The market for Azilsartan Impurity 19 is driven by ongoing research and development in the pharmaceutical industry, particularly in the area of hypertension treatment. Recent trends indicate a growing focus on quality control and impurity analysis in drug manufacturing, which has increased the demand for accurate and reliable impurity standards. Emerging research is also exploring new methods for impurity detection and removal, which could further influence market dynamics.

Waste containing Azilsartan Impurity 19 should be collected in sealed, labeled containers and stored in a secure, well-ventilated area. It should be disposed of through professional waste disposal services that are compliant with local regulations. Incineration is a common method, but the temperature must be carefully controlled to prevent the release of harmful substances. Environmental protection measures, such as neutralizing any potential acidic or basic components, should be followed to ensure minimal environmental impact.